Solvonis Therapeutics PLC (SVNS)

Currency in GBP
0.37
+0.04(+12.31%)
Closed·
SVNS Scorecard
Full Analysis
Significant return over the last week
Trading near 52-week High
SVNS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.330.38
52 wk Range
0.110.38
Key Statistics
Bid/Ask
0.34 / 0.38
Prev. Close
0.33
Open
0.35
Day's Range
0.33-0.38
52 wk Range
0.11-0.38
Volume
163.03M
Average Volume (3m)
95.95M
1-Year Change
43.48%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SVNS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
1.60
Upside
+332.43%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Solvonis Therapeutics PLC News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Solvonis Therapeutics PLC Company Profile

Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops novel medicines for addiction and mental health disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-clinical stage product candidate includes SVN-SDN-14 for the treatment of post-traumatic stress disorder. The company was formerly known as Graft Polymer (UK) Plc and changed its name to Solvonis Therapeutics plc in January 2025. Solvonis Therapeutics plc was incorporated in 2017 and is headquartered in London, the United Kingdom.

Compare SVNS to Peers and Sector

Metrics to compare
SVNS
Peers
Sector
Relationship
P/E Ratio
−14.1x−0.4x2.0x
PEG Ratio
−0.15−0.220.00
Price/Book
6.6x1.3x1.6x
Price / LTM Sales
-1.1x1.3x
Upside (Analyst Target)
384.8%48.4%20.1%
Fair Value Upside
Unlock9.5%0.6%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 1.60
(+332.43% Upside)

Earnings

Latest Release
May 07, 2025
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

SVNS Income Statement

People Also Watch

1.68
CYK
0.00%
0.13
CLAI
-7.27%
0.01
VULT
0.00%
4.42
HAMA
-0.67%

FAQ

What Stock Exchange Does Solvonis Therapeutics Trade On?

Solvonis Therapeutics is listed and trades on the London Stock Exchange stock exchange.

What Is the Stock Symbol for Solvonis Therapeutics?

The stock symbol for Solvonis Therapeutics is "SVNS."

What Is the Solvonis Therapeutics Market Cap?

As of today, Solvonis Therapeutics market cap is 20.35M.

What Is Solvonis Therapeutics's Earnings Per Share (TTM)?

The Solvonis Therapeutics EPS (TTM) is -0.00.

From a Technical Analysis Perspective, Is SVNS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Solvonis Therapeutics Stock Split?

Solvonis Therapeutics has split 0 times.

How Many Employees Does Solvonis Therapeutics Have?

Solvonis Therapeutics has 3 employees.

What is the current trading status of Solvonis Therapeutics (SVNS)?

As of 12 Aug 2025, Solvonis Therapeutics (SVNS) is trading at a price of 0.37, with a previous close of 0.33. The stock has fluctuated within a day range of 0.33 to 0.38, while its 52-week range spans from 0.11 to 0.38.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.